Skip to Main Content

Paper Details

Higher-dose venetoclax with measurable residual disease-guided azacitidine discontinuation in newly diagnosed acute myeloid leukemia.
Haematologica
5
2023
Author NameAffiliation
Amanda WintersCenter for Cancer and Blood Disorders, University of Colorado, Aurora CO.
Maria AmayaUniversity of Colorado, Aurora CO.
Clayton A SmithUniversity of Colorado, Aurora CO.
Veronica Clavijo JordanUniversity of Colorado, Aurora CO.
Veronica Clavijo JordanUniversity of Colorado, Aurora CO.
Brett M StevensUniversity of Colorado, Aurora CO.
Mohammad MinhajuddinUniversity of Colorado, Aurora CO.
Shanshan PeiUniversity of Colorado, Aurora CO.
Diana AbbottCenter for Innovative Design and Analysis, University of Colorado, Aurora CO.
Daniel A PollyeaUniversity of Colorado, Aurora CO. .
  • 1 - 10

Datasets